Open original FDA record ↗Recall record
- FDA identifier
- Z-1321-2010
- Company in FDA record
- Agendia Inc
- FDA classification date
- Apr 12, 2010
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 20, 2026
- Recall classification
- Unknown — no matched enforcement classification
Reason stated in the source
Over a period of about 6 months in about 15% of results provided Agendia has been "over reporting" the chance of metastasis risk being 29% risk of recurrence instead of 10% risk. This over reporting of risk did not cause direct injury to patients. However, if used by physicians as the sole basis for decision-making, affected patients may have received unnecessary therapy.
Source facts
- Action
- Communication with physicians was initiated by the firm's Chief Medical Officer on March 3, 2010. The firm's representatives will meet with treating physicians in person while having the corrected results in hand to inform each in person of the action, to allow a decision of the best course of action. Physicians will be provided with background information on the issue at hand and corrected results. As follow up, the physician would receive a corrected report per patient by FedEx in order to register the reception of corrected information. Because each user received a personal visit, no other contact information was planned or provided by Agendia.
- Initiated
- 2010-03-03
- Root cause
- Other
- Terminated
- 2010-06-18
- Distribution
- Nationwide.
- Recall number
- Z-1321-2010
- Recall status
- Terminated
- CDRH record ID
- 89513
- FDA classified
- 2010-04-12
- Recall event number
- 54930